Scripps Updates in Diabetes Management 2025

2025 Updates in Diabetes Management Presented by Scripps Whittier Diabetes Institute
September 27, 2025 San Diego Marriott • La Jolla, California
Conference Overview
Scripps Whittier Diabetes Institute’s 2025 Updates in Diabetes Management program will showcase the latest advancements in the diagnosis and treatment of both type 1 and type 2 diabetes. The program will cover recent developments in medications, nutrition, surgical interventions, and diabetes technology. enowned experts actively involved in patient care and clinical trials related to diabetes management will lead the course. Attendees will receive essential context to incorporate relevant information into their practice, ultimately aiming to enhance the quality of life for patients living with diabetes.
Educational Objectives
After attending this live activity, participants should be able to:

Outline the considerations and precautions required when managing diabetes in patients with coexisting renal and/or cardiac disease.
Illustrate the use of glucose monitoring technologies to accurately track patient blood glucose levels.
Examine evidence-based strategies for weight loss, including dietary interventions, medications, and surgical options.
Incorporate updated practice recommendations for treating patientswith diabetes from both primary care and specialist perspectives.
Recognize and address health disparities that may adversely affect patient care during clinical encounters.

The Scripps Updates in Diabetes Management 2025 symposium is best for endocrinologists, primary care physicians, internists, advanced practice providers, and allied health professionals who want, evidence‑based updates on the latest therapies, technologies, and strategies for managing diabetes.
Who Should Attend

Endocrinologists specializing in diabetes and metabolic disorders.
Primary care physicians and internists who manage diabetes in outpatient settings.
Advanced practice providers (NPs, PAs) working in endocrinology or primary care clinics.
Certified diabetes educators, nurses, and pharmacists involved in patient education and medication management.
Residents and fellows in endocrinology or internal medicine preparing for subspecialty practice.

What You’ll Learn

Latest pharmacologic therapies: GLP‑1 receptor agonists, SGLT2 inhibitors, insulin innovations, and combination therapies.
Advances in diabetes technology: continuous glucose monitoring (CGM), insulin pumps, and digital health tools.
Guideline updates: ADA and AACE recommendations for diagnosis, treatment, and complication prevention.
Management of comorbidities: cardiovascular disease, kidney disease, obesity, and neuropathy in diabetic patients.
Patient‑centered strategies: lifestyle interventions, nutrition, and behavioral health integration.

 
+ Topics:
Conference Agenda: September 27, 2025

6:45 a.m. Registration, Breakfast & View Exhibits
7 a.m. Non-CME Breakfast Symposium Hosted by Eli Lilly Mounjaro® (tirzepatide) Product Theater Samantha Harris, MD
7:50 a.m. Welcome & Educational Overview
BACK TO BASICS ADA STANDARD OF CARE UPDATES
8 a.m. Emphasis on Obesity/Prevention Strategies Samantha Harris, MD
8:15 a.m. Geriatric Diabetes Targets & Management Athena Philis-Tsimikas, MD
8:30 a.m. Options for Treatment of Adolescents with Diabetes Puja Singh, MD
8:45 a.m. The Power of Psych William Polonsky, PhD
9 a.m. Plant-Based Protein: What’s the Evidence? Caitlin Dahl, RDN
9:15 a.m. Panel Discussion/Q&A
9:45 a.m. Is There an Optimal Approach to Medical Management for Type 2 Diabetes? Alice Cheng, MD
10:25 a.m. Break & View Exhibits
DIABETES & COMORBID CONDITIONS APPROACHES TO TREATING HEART FAILURE IN DIABETES AND OBESITY
10:50 a.m. GLP-1 Agonists: Preventing CV Disease & Treating Heart Failure Pam Taub, MD
11:10 a.m. SGLT Inhibitors: Preventing CV Disease & Treating Heart Failure Jia Shen, MD
INNOVATIVE TREATMENTS FOR OBSTRUCTIVE SLEEP APNEA AND LIVER DISEASE IN DIABETES AND OBESITY
11:30 a.m. Obstructive Sleep Apnea Nancy Hsu, MD
11:50 a.m. Metabolic Associated Fatty Liver Disease/Metabolic Associated Steatohepatitis Paul Pockros, MD
12:10 p.m. Panel Discussion/Q&A
12:30 p.m. Non-CME Lunch Symposium Hosted by Madrigal Pharmaceuticals Rezdiffra: Unlocking the Potential of a Liver-Directed Treatment Nadege Gunn, MD
ADVANCED DIABETES CARE FOR SPECIAL POPULATIONS
1:30 p.m. Are We Missing a Diagnosis in Hard-to-Treat Diabetes? Results from CATALYST Athena Philis-Tsimikas, MD
1:45 p.m. Diabetes & Sexual Dysfunction: What Do We Tell Our Patients? Alyssa Yee, MD
2:05 p.m. GLP-1 Agonists and SGLT2i in Type 1 Diabetes: What is the Evidence? Robert Thomas, MD, PhD
2:25 p.m. Real Patients Get Real: Panel Discussion/Q&A
2:45 p.m. Break & View Exhibits
DIGITAL INTERVENTIONS FOR DIABETES—SUPERPOWERS OR TECH OVERLOAD
3 p.m. Latest Scoop on CGM and Smart Insulin Pumps Athena Philis-Tsimikas, MD
3:15 p.m. Hospital to Home Transitions of Care with & without a Medical Home Laura Talavera, MSN, MPH, RN, & Lauren Vincent, MD
3:45 p.m. Enhancing Care with Remote Patient Monitoring Shane Thielman
4:15 p.m. Panel Discussion/Q&A
4:30 p.m. Adjourn Topics, times and speakers are subject to change